Recent focus on Zimmer Biomet Holdings (ZBH) centers on its dividend track record and payout safety, which contrasts with softer recent share returns and has prompted investors to reassess the stock’s income appeal.

At a share price of $88.73, Zimmer Biomet’s near term share price momentum has been mixed. The 7 day share price return is 3.15%, but the 30 day share price return shows a 6.35% decline. Longer term total shareholder returns over one, three and five years have also been negative, suggesting sentiment has been fading despite its focus on dependable dividends.

If this dividend story has you rethinking concentration in a single name, it could be a good moment to widen your net with our screener of 22 top founder-led companies.

With a value score of 5, an indicated intrinsic discount of 48.36% and a market price of $88.73 against a consensus target of about $102.74, is Zimmer Biomet quietly offering upside, or is the market already pricing in its future growth?

Most Popular Narrative: 13.3% Undervalued

Zimmer Biomet’s most followed narrative pegs fair value at about $102.39, above the last close at $88.73, which puts the spotlight on how its product pipeline and earnings path might support that gap.

The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is increasing adoption of premium offerings, enabling margin expansion due to product mix and driving recurring revenues through connected care ecosystems, supporting higher net margins and earnings predictability.

Curious what earnings power that kind of product mix is aiming for, and what multiple the narrative thinks the market will accept for it? The full storyline sets out a detailed revenue ramp, margin uplift and valuation bridge that connects today’s price to that $102.39 fair value mark.

Result: Fair Value of $102.39 (UNDERVALUED)

However, this hinges on pricing and reimbursement pressure, as well as tougher competition in robotics and core orthopedics, not undercutting the earnings and margin story investors are buying into.

Build Your Own Zimmer Biomet Holdings Narrative

If you think the story should look different, or you prefer to work from your own numbers, you can build a custom thesis in just a few minutes by starting with Do it your way.

A great starting point for your Zimmer Biomet Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at one stock. Use focused stock lists to spot opportunities other investors might overlook.

• Target potential value plays by scanning our list of 55 high quality undervalued stocks that pair solid fundamentals with prices the market may be discounting.
• Zero in on resilience with a curated set of 81 resilient stocks with low risk scores that score well on our risk checks and may help steady your overall returns.
• Hunt for tomorrow’s standouts by reviewing a screener containing 25 high quality undiscovered gems that combines quality metrics with lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.